An	an	O	O	O	O
evaluation	evaluation	O	O	O	O
of	of	O	O	O	O
amikacin	amikacin	CHEMICALS	O	OTHERS	I
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
hematology/oncology	hematology/oncology	O	O	O	O
population	population	O	O	O	O
.	.	O	O	O	O

Amikacin	amikacin	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
an	an	O	O	O	O
aminoglycoside	aminoglycoside	CHEMICALS	O	OTHERS	I
commonly	commonly	O	O	O	O
used	used	O	O	O	O
to	to	O	O	O	O
provide	provide	O	O	O	O
empirical	empirical	O	O	O	O
double	double	O	O	O	O
gram-negative	gram-negative	O	O	O	O
treatment	treatment	O	O	O	O
for	for	O	O	O	O
febrile	febrile	O	DISEASE	OTHERS	I
neutropenia	neutropenia	O	DISEASE	OTHERS	I
and	and	O	O	O	O
other	other	O	O	O	O
suspected	suspected	O	O	O	O
infections	infections	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Strategies	strategies	O	O	O	O
of	of	O	O	O	O
extended-interval	extended-interval	O	O	O	O
and	and	O	O	O	O
conventional	conventional	O	O	O	O
dosing	dosing	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
utilized	utilized	O	O	O	O
extensively	extensively	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
general	general	O	O	O	O
medical	medical	O	O	O	O
population	population	O	O	O	O
;	;	O	O	O	O
however	however	O	O	O	O
,	,	O	O	O	O
data	data	O	O	O	O
are	are	O	O	O	O
lacking	lacking	O	O	O	O
to	to	O	O	O	O
support	support	O	O	O	O
a	a	O	O	O	O
dosing	dosing	O	O	O	O
strategy	strategy	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
hematology/oncology	hematology/oncology	O	O	O	O
population	population	O	O	O	O
.	.	O	O	O	O

To	to	O	O	O	O
evaluate	evaluate	O	O	O	O
amikacin-associated	amikacin-associated	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
in	in	O	O	O	O
an	an	O	O	O	O
adult	adult	O	O	O	O
hematology/oncology	hematology/oncology	O	O	O	O
population	population	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
prospective	prospective	O	O	O	O
,	,	O	O	O	O
randomized	randomized	O	O	O	O
,	,	O	O	O	O
open-label	open-label	O	O	O	O
trial	trial	O	O	O	O
was	was	O	O	O	O
conducted	conducted	O	O	O	O
at	at	O	O	O	O
a	a	O	O	O	O
university-affiliated	university-affiliated	O	O	O	O
medical	medical	O	O	O	O
center	center	O	O	O	O
.	.	O	O	O	O

Forty	forty	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
diagnosis	diagnosis	O	O	O	O
consistent	consistent	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
hematologic/oncologic	hematologic/oncologic	O	O	O	O
disorder	disorder	O	O	O	O
that	that	O	O	O	O
required	required	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
an	an	O	O	O	O
aminoglycoside	aminoglycoside	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
randomized	randomized	O	O	O	O
to	to	O	O	O	O
either	either	O	O	O	O
conventional	conventional	O	O	O	O
or	or	O	O	O	O
extended-interval	extended-interval	O	O	O	O
amikacin	amikacin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
occurrence	occurrence	O	O	O	O
of	of	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
by	by	O	O	O	O
means	means	O	O	O	O
of	of	O	O	O	O
an	an	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
serum	serum	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
evaluation	evaluation	O	O	O	O
of	of	O	O	O	O
efficacy	efficacy	O	O	O	O
via	via	O	O	O	O
amikacin	amikacin	CHEMICALS	O	OTHERS	I
serum	serum	O	O	O	O
concentrations	concentrations	O	O	O	O
with	with	O	O	O	O
respective	respective	O	O	O	O
pathogens	pathogens	O	O	O	O
were	were	O	O	O	O
assessed	assessed	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
occurrence	occurrence	O	O	O	O
of	of	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
was	was	O	O	O	O
similar	similar	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
conventional	conventional	O	O	O	O
and	and	O	O	O	O
extended-interval	extended-interval	O	O	O	O
groups	groups	O	O	O	O
,	,	O	O	O	O
at	at	O	O	O	O
10	10	O	O	O	O
%	%	O	O	O	O
and	and	O	O	O	O
5	5	O	O	O	O
%	%	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
=	=	O	O	O	O
1.00	1.00	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Six	six	O	O	O	O
patients	patients	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
conventional	conventional	O	O	O	O
group	group	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
positive	positive	O	O	O	O
culture	culture	O	O	O	O
,	,	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
none	none	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
extended-interval	extended-interval	O	O	O	O
group	group	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
=	=	O	O	O	O
0.002	0.002	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
occurrence	occurrence	O	O	O	O
of	of	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
was	was	O	O	O	O
similar	similar	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
two	two	O	O	O	O
dosing	dosing	O	O	O	O
regimens	regimens	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
the	the	O	O	O	O
distribution	distribution	O	O	O	O
of	of	O	O	O	O
risk	risk	O	O	O	O
factors	factors	O	O	O	O
was	was	O	O	O	O
variable	variable	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
two	two	O	O	O	O
groups	groups	O	O	O	O
.	.	O	O	O	O

Efficacy	efficacy	O	O	O	O
could	could	O	O	O	O
not	not	O	O	O	O
be	be	O	O	O	O
assessed	assessed	O	O	O	O
.	.	O	O	O	O

